You are here:  > Browse Articles

Short communication

Inhibition of novel reassortant avian influenza H7N9 virus infection in vitro with three antiviral drugs, oseltamivir, peramivir and favipiravir

Rui-Yuan Cao, Jun-Hai Xiao, Bin Cao, Song Li, Yohichi Kumaki, Wu Zhong

Corresponding author name: Yohichi Kumaki; Wu Zhong
Corresponding author e-mail:;

Citation: Antiviral Chemistry & Chemotherapy 2014; 23:237-240
doi: 10.3851/IMP2672

Date accepted: 24 July 2013
Date published online: 15 August 2013


Background: A novel reassortant avian-origin influenza A (H7N9) virus was isolated from respiratory specimens obtained from three patients and was identified as H7N9 in China. Antiviral agents are required to treat patients with avian influenza H7N9 virus infection.

Methods: In this study, we assessed the antiviral potential of oseltamivir, peramivir, favipiravir (T-705), amantadine and rimantadine against novel reassortant avian-origin influenza H7N9 virus in vitro.

Results: All three avian influenza H7N9 virus strains were sensitive to oseltamivir, peramivir and favipiravir (T-705), but resistant to amantadine and rimantadine.

Conclusions: Our data show a pattern of antiviral sensitivity for this novel H7N9 strain of influenza that suggests the compounds oseltamivir, peramivir and favipiravir should be useful for therapy.


Copyright © 2020 Nucleus Holdings Ltd. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.